| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2702 |
| Trial ID | NCT04910971 |
| Disease | Inflammation | Vaccine Adverse Reaction | Coronavirus Infectious Disease |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Recruitment status | Unknown |
| Title | Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year |
| Year | 2021 |
| Country | United States |
| Company sponsor | LifeBridge Health |
| Other ID(s) | 1707882 |
| Vector information | |||
|
|||
| Cohort1: BNT162b2 | |||||
|
|||||
| Cohort2: mRNA-1273 | |||||
|
|||||